Evidence map›Paper›PMID 29373926›Full record

ArticleCartilage2019

Treatment of Knee Osteoarthritis with Bone Marrow-Derived Mononuclear Cell Injection: 12-Month Follow-up.

Valdis Goncars, Konstantins Kalnberzs, Eriks Jakobsons, Ilze Enģele, Ieva Briede, Kristaps Blums, Kristaps Erglis, Martins Erglis, Liene Patetko, Indrikis Muiznieks and 1 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cartilage, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Adipose-derived and bone marrow aspirate concentrate injections for osteoarthritis: A scoping review.PM & R : the journal of injury, function, and rehabilitation · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Valdis Goncars1 Latvian State Hospital for Traumatology and Orthopaedics, University of Latvia, Riga, Latvia.
Konstantins Kalnberzs1 Latvian State Hospital for Traumatology and Orthopaedics, University of Latvia, Riga, Latvia.
Eriks Jakobsons2 Pauls Stradins Clinical University Hospital, Cell Transplantation Centre, Institute of Cardiology, University of Latvia, Riga, Latvia.
Ilze Enģele3 Riga East University Hospital, Radiologist, Riga, Latvia.
Ieva Briede2 Pauls Stradins Clinical University Hospital, Cell Transplantation Centre, Institute of Cardiology, University of Latvia, Riga, Latvia.
Kristaps Blums4 Riga East university Hospital, University of Latvia, Latvia.
Kristaps Erglis2 Pauls Stradins Clinical University Hospital, Cell Transplantation Centre, Institute of Cardiology, University of Latvia, Riga, Latvia.
Martins Erglis2 Pauls Stradins Clinical University Hospital, Cell Transplantation Centre, Institute of Cardiology, University of Latvia, Riga, Latvia.
Liene Patetko2 Pauls Stradins Clinical University Hospital, Cell Transplantation Centre, Institute of Cardiology, University of Latvia, Riga, Latvia.
Indrikis Muiznieks5 Division of Microbiology and Biotechnology, Department of Biology, University of Latvia, Riga, Latvia.
Andrejs Erglis2 Pauls Stradins Clinical University Hospital, Cell Transplantation Centre, Institute of Cardiology, University of Latvia, Riga, Latvia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the main symptoms of knee osteoarthritis (OA) and tissue structure changes after a single dose bone marrow-derived mononuclear cell (BM MNC) intra articular injection. Case series study. Patients with knee OA Kellgren Lawrence (K-L) grade II and III received 1 injection of BM MNC. The clinical results were analyzed with the Knee injury and Osteoarthritis Outcome Score (KOOS) and Knee Society Score (KSS) before, 3, 6, and 12 months after injection. Radiological evaluation was performed with a calibrated x-ray and the magnetic resonance (MR) imaging before and 6 to 7 months postinjection.

resultsA total of 34 knees were treated with BM MNC injections. Mean (±SD) age of patient group was 53.96 ± 14.15 years; there were 16 males, 16 females, KL grade II, 16; KL grade III, 18. The average injected count of BM MNCs was 45.56 ± 34.94 × 10

conclusionsThe single dose BM MNC partially reduces clinical signs of the knee osteoarthritis stage II/III and in some cases, decreases degenerative changes in the joint building tissue over 12-month period.

Indexed as

AdultFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansInjections, Intra-ArticularKnee JointLeukocytes, MononuclearMagnetic Resonance ImagingMaleMiddle AgedOsteoarthritis, KneeRadiographySeverity of Illness IndexTreatment Outcomearticular cartilagebone marrowcartilage regenerationknee magnetic resonance imagingknee osteoarthritismononuclear cellsosteoarthritis disease modificationstem cellstissue

Identifiers

PMID29373926
PMCPMC6376566

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.